Scarica l'app Stockscreener
25.97
1.85%
-0.49
Dopo l'orario di chiusura:
25.54
-0.43
-1.66%
Precedente Chiudi:
$26.46
Aprire:
$26.46
Volume 24 ore:
548.53K
Relative Volume:
0.62
Capitalizzazione di mercato:
$1.54B
Reddito:
$13.05M
Utile/perdita netta:
$-60.54M
Rapporto P/E:
-22.39
EPS:
-1.16
Flusso di cassa netto:
$-37.82M
1 W Prestazione:
-6.41%
1M Prestazione:
+11.22%
6M Prestazione:
-41.12%
1 anno Prestazione:
-42.80%
Intervallo 1D:
$25.72
$26.99
Intervallo di 1 settimana:
$25.72
$28.39
Portata 52W:
$22.48
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Confronta JANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
25.97 | 1.57B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating for Janux Therapeutics - TipRanks
What analysts say about Janux Therapeutics Inc. stockStrongest growth potential - PrintWeekIndia
Is Janux Therapeutics Inc. stock a growth or value playHigh-profit capital plays - jammulinksnews.com
What drives Janux Therapeutics Inc. stock priceOutstanding capital appreciation - Autocar Professional
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day - Business Wire
Janux Therapeutics Inc. Stock Analysis and ForecastRapid wealth multiplication - Autocar Professional
Is Janux Therapeutics Inc. a good long term investmentFree Predictions - Autocar Professional
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
Strategic Initiatives and Long-Term Potential Drive Buy Rating for Janux Therapeutics Inc. - TipRanks
Teacher Retirement System of Texas Sells 884 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nisa Investment Advisors LLC - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Upgraded at Wall Street Zen - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $91.89 Consensus PT from Analysts - Defense World
E.W. Scripps (NASDAQ:SSP) Lowered to Sell Rating by Wall Street Zen - Defense World
Janux Therapeutics (JANX) Soars 2.31% on R&D Day Announcement - AInvest
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - BioSpace
Janux Therapeutics to Showcase New Preclinical Programs at Virtual R&D Day - AInvest
September 19th Options Now Available For Janux Therapeutics (JANX) - Nasdaq
How Janux Therapeutics Inc. stock performs during market volatilityExplosive Growth Potential - Newser
Why Janux Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes Janux Therapeutics Inc. stock price move sharplyProfessional Stock Screener - Newser
Raymond James Financial Initiates Coverage on Janux Therapeutics (NASDAQ:JANX) - Defense World
Argus Initiates Coverage on CoreWeave (NASDAQ:CRWV) - Defense World
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Allspring Global Investments Holdings LLC Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Raymond James initiates Janux Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Raymond James Initiates Janux Therapeutics at Outperform With $65 Price Target - MarketScreener
Janux Therapeutics initiated with an Outperform at Raymond James - TipRanks
KBC Group NV Invests $66,000 in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
(JANX) On The My Stocks Page - news.stocktradersdaily.com
Janux Therapeutics Insiders Sell US$5.6m Of Stock, Possibly Signalling Caution - simplywall.st
Top Defense Stocks To Follow Now – July 1st - Defense World
2025's 10 Worst-Performing Stocks | Investing - US News Money
Janux Therapeutics: Riding Momentum into the Russell Indices and Beyond - AInvest
GAMMA Investing LLC Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
When (JANX) Moves Investors should Listen - news.stocktradersdaily.com
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - MSN
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):